Fibromyalgia & Bio-Resonance
A Descriptive Study on Fibromyalgia and Bio-Resonance was conducted, collecting information from nine patients diagnosed with Fibromyalgia Syndrome. The study took place from September 2004 to October 2007 at a private medical institution in San Jose, Costa Rica.
By:
LUIS CARLOS ORDOÑEZ MATAMOROS
MD Code 6333
Mobile: (506) 83952505 / E Mail: luiscordonez@yahoo.com
Descriptors:
The study considered positive symptoms, high positive symptoms, low positive symptoms, sensitive painful spots, Bio-Resonance therapy, Exotherapy, Endotherapy, individuality, and most repeated therapies.
Justification and Objectives:
The study aimed to address the need to alleviate the pain experienced by over 2% of the population diagnosed with fibromyalgia. Traditional medications used to manage symptoms often come with multiple side effects and do not offer a chance to reduce dosage. Therefore, the study sought to apply Bio-Resonance technology as a supportive measure to conventional treatments for fibromyalgia patients.
Method:
This study employed a prospective design, systematically gathering information from the initial consultation to the last day of specific treatment. Follow-up evaluations were conducted months or years after treatment completion.
Population:
Thirteen individuals voluntarily participated in the study. They had previously been diagnosed with Fibromyalgia by rheumatologists and sought consultation between September 2004 and November 2007 at an office located in Mediplaza, Escazu, San Jose, Costa Rica. Out of the 13 patients, 11 were selected based on confirmed Fibromyalgia diagnoses, while two were rejected and treated differently due to unconfirmed symptoms during examination. Among the 11 selected patients, two did not return after the initial evaluation. The study collected information from seven patients who received full therapy and two patients who received less than two-thirds of the therapy. All patients in the study were female, with an average age of 41 (ranging from 20 to 52 years). Symptoms first appeared in patients between 2 and 24 years before the study. Diagnosis of Fibromyalgia Syndrome was confirmed based on medical history, complete physical evaluation, and adherence to the methodology outlined by the American Association of Rheumatology for symptoms and painful spots.
Hypothesis:
The hypothesis of the study was that patients treated with Bio-Resonance would experience symptom improvement and a reduction in the number of painful spots, leading to a decrease of over 50% in the use of pharmaceuticals.
*Endotherapy: When the device uses the body’s information and modifies it.
*Exotherapy: When the device sends predetermined information into the body.
Materials:
Forms were designed to gather information for the study, along with a diagram of painful spots specific to Fibromyalgia. These forms were administered to all patients at the beginning of treatment, approximately 4 weeks into treatment, at the end of treatment, and during subsequent evaluations. Some patients were unable to complete all evaluations due to reasons such as relocation or inability to be located. When patients responded with doubt or «medium» to the question regarding high or low intensity, it was always qualified as high. When patients were uncertain about the absence or low presence of a symptom, it was always qualified as low.
Treatment:
The treatment protocol was developed in collaboration with the Hippocampus Institute in Budapest, particularly with Gabor Lednyiczky, the institute’s scientific president. After several adjustments made between September 2004 and January 2007, a treatment protocol consisting of 7 therapies with 26 programs using Mobile CellCom, 30 therapies with 60 programs using LENYO Lux, initial evaluation, and emotional therapy with LIFE system was established. The treatment lasted for two months.
Application of Bio-Resonance Therapies:
For the seven patients who received full therapy:
- Total number of therapies applied using LIFE system: 30, with a range of 2 to 8 therapies.
- Average number of therapies applied with LIFE system: 4.29
- Total number of therapies applied using LENYO Lux: 232, with a range of 22 to 44 therapies.
- Average number of therapies applied with LENYO Lux: 33.1
- Total number of therapies applied using Mobile CellCom: 87, with a range of 7 to 27 therapies.
- Average number of therapies applied with Mobile CellCom: 12.4
For the two patients who received incomplete therapy:
- Total number of therapies applied using LIFE system: 4, with a range of 2 to 2 therapies.
- Average number of therapies applied with LIFE system: 2
- Total number of therapies applied using LENYO Lux: 65, with a range of 29 to 36 therapies.
- Average number of therapies applied with LENYO Lux: 32.5
- Total number of therapies applied using Mobile CellCom: 9, with a range of 3 to 6 therapies.
- Average number of therapies applied with Mobile CellCom: 4.5
Out of the 26 definitive programs in the protocol, none were applied to all patients, as the study aimed to determine the most effective programs. Some selected programs for the definitive protocol were never applied to the initial patients.
The following programs were most frequently used:
- With Mobile CellCom: Programs 327 and 328 were applied to 6 patients, nervous system program 308, 310, and 400 to 5 patients, muscle and soft tissue pain program 312, 463, 465, 290, and 512 to 4 patients, and programs 126, 127, and 124 for harmonization of quadrants and emotional blockages to 3 patients.
- With LENYO Lux: Programs 75 (Liver), 145 (Electro Smog), 76 (Aggression), 106 (Pain), 123 (Energetic Balance), 84 (Nervous System), 124 (Nerves), and 144 (Adrenals) were applied repeatedly.
- With LIFE System: Each patient received an individual approach.
Methodology:
The final protocol employed in the study consisted of the following steps:
- General Bio-communication evaluation and application of Biofeedback to address specific disorders identified through the LIFE system.
- Assessment of inadequate responses to vitamins, minerals, amino acids, and determination of necessary supplementation.
- Evaluation of inadequate responses to certain foods and implementation of dietary restrictions.
- Recommendation to eliminate the consumption of sugar and artificial foods containing preservatives, additives, flavors, colorants, etc.
- Recommendation to take a tablespoon of flaxseed oil and multi-amino free form with each meal and before bed.
- Prescribing Albendazole 800 mg in two doses of 400 mg every 15 days for five patients.
- Two months of daily Bio-Resonance treatments with LENYO Lux five days a week, along with a weekly therapy session using Mobile CellCom (some patients were unable to follow the recommended frequency due to distance, cost, or time constraints).
- Evaluation and Biofeedback on the emotional aspects of the identified disorders using the LIFE System’s emotional profile.
- Advising patients to increase water consumption, ensuring they consumed at least one glass of water after every therapy session.
Results:
- Group that received full therapy:
Comparison of information from the beginning of treatment to the last evaluation of the seven patients who received full treatment showed the following advancements:
-
- A reduction in the number of painful spots from an average of 15.1 at the beginning to 7.71 at the last evaluation, with a range of 18 to 11 painful spots at the beginning and 12 to 2 at the last evaluation, representing a 49% reduction.
- A reduction in the total number of symptoms from 70 at the beginning to 48 at the last evaluation, a reduction of 38.57%.
- A reduction in high positive symptoms from an average of 56 at the beginning to 15 at the last evaluation, with a range of 11 at the beginning to 5 at the last evaluation, representing a 73% reduction.
- A reduction in the need for analgesics and anti-inflammatory medications from an average of 13.7 per patient per week to 0.29 per week at the last evaluation, reducing consumption by 85%.
- Group that received incomplete therapy:
Comparison of information from the beginning of treatment to the last evaluation of the two patients who received less than two-thirds of the treatment showed the following advancements:
-
- A 25% reduction in the number of painful spots, resulting in a significant reduction in pain intensity.
- A 66% reduction in high positive symptoms.
- A 30% reduction in medication needs.
Conclusion and Discussion:
- Bio-Resonance is an effective technique for reducing the painful and distressing symptoms experienced by patients with Fibromyalgia syndrome, significantly improving their quality of life, as well as that of their families and work environments.
- Despite improvements, some symptoms such as low concentration (66%), insomnia (75%), muscular pain (25%), mental deterioration (40%), and numbness (33%) persisted at the end of treatment or during the last evaluation.
- The reduction in medication needs serves as clear evidence of symptom reduction and improvement in patients’ quality of life.
- The decrease in the number of high positive points and symptoms raises questions regarding the initial diagnosis of Fibromyalgia and its incurable nature, especially in cases where reductions were significant.
- Long-term responses to Bio-Resonance and the treatment protocol should be monitored over an extended period.
- The study did not evaluate the social and economic costs of the disease and its reduction through Bio-Resonance treatment. However, it can be inferred that the decrease in medication needs reduces collateral effects and associated costs, as well as the personal, social, and economic burdens experienced by patients.
- The small number of patients in this study compared to the magnitude of the problem highlights the need for a larger sample size for statistically valid results. However, the fact that all patients, even those who did not receive full treatment, showed improvement in their symptoms strongly supports the recommendation for Bio-Resonance as a supportive treatment for Fibromyalgia, challenging the notion of its incurability.
- The reoccurrence or persistence of symptoms and painful spots in some patients after six months, as well as the use of occasional painkillers and anti-inflammatory medications despite not meeting the parameters for Fibromyalgia diagnosis after treatment, suggests the need for reinforcement therapy every six months for one week. On the other hand, the complete disappearance of symptoms in some patients raises doubts about previous assumptions.
- A double-blind trial with four groups is recommended to further explore the efficacy and cost-effectiveness of various treatment approaches, including the control group.
Protocol Recommendation:
The recommended effective and cost-effective protocol consists of:
- Two daily sessions of approximately 1.5 hours for eight weeks using LENYO Lux.
- One session of a maximum of 20 minutes with Mobile CellCom each week for seven weeks.
- One initial evaluation lasting one hour, emotional therapy lasting two hours, and a final evaluation at the end of treatment using the LIFE System.
Special Thanks:
Special thanks are extended to Miss Renata Beffa for introducing the Bio-Resonance technology in 2003 and highlighting its potential in supporting prevention and addressing health issues. Thanks are also extended to Scientist Gabor Lednyiczky, the teacher in the application of this new technology.
Bibliography:
Effects of extremely low frequency electromagnetic field (EMF) on collagen type I mRNA expression and extracellular matrix synthesis of human osteoblastic cells
Schmidt, J.; Heermeier, K., Spanner, M.: “Institut fur Molekulare Virologie, GSF-Forschungszentrum für Umwelt und Gesundheit”. Neuherberg, Germany
Träger, J.: “Orthopädische Klinik”, Technische Universität München. München, Germany
Gradinger, R.: “Orthopädische Klinik”, Universität Lübeck, Lübeck, Germany
Kraus, W.: “Institut für Medizinische Physik”. München, Germany
Thomas F. Valone
Integrity Research Institute, 1220 L Street NW, Suite 100-232
Washington DC 20005
Presented at Whole Person Healing Conference & Tesla Energy Science Conference, 2003
Jerabek, J.; Pawluk, W.: “Magnetic Therapy in Eastern Europe a review of 30 years of research”. 1998
Ruth,B. and F.A.Popp: Experimentelle Untersuchungen zur ultraschwachen Photonenemission biologischer Systeme. Z.Naturforsch.31
Ruth, B. In: Electromagnetic Bio-Information (F.A.Popp, G.Becker, H.L.König and W.Peschka, eds.), Urban &Schwarzenberg, München-Wien-Baltimore 1979. This paper contains the historical background of biophotons.
Popp, F.A.: Biophotonen. Ein neuer Weg zur Lösung des Krebsproblems. Schriftenreihe Krebsgeschehen, Vol.6, Verlag für Medizin, Dr.Ewald Fischer,Heidelberg 1976.
Popp,F.A., Ruth,B., Bahr,W., Böhm,J., Grass,P., Grolig,G., Rattemeyer,M., Schmidt,H.G., and Wulle,P.:Emission of visible and ultraviolet radiation by active biological systems. Collective Phenomena (Gordon&Breach), Vol.3 (1981), pp.187-214.
Rattemeyer, M., Popp,F.A., and Nagl,W.: Evidence of photon emission from DNA in living systems. Naturwissenschaften 68 (1981), 572-573.
Popp,F.A., Gurwitsch,A.A., Inaba, H., Slawinski, J., Cilento G., van Wijk, R., Chwirot B., and Nagl,W.: Biophoton Emission (Multi-Author Review), Experientia 44 (1988), 543-600.
Popp,F.A., Gu,Q., and Li, K.H.:Biophoton Emission: Experimentell Background and Theoretical Approaches. Modern Physics Letters B8 (1994), 1269-1296.
Chang, J.J., Fisch, J., and Popp,F.A.:Biophotons. Kluwer Academic Publishers, Dordrecht-Boston-London 1998.
Bajpai, R.P., Popp,F.A., van Wijk, R., Niggli,H., Beloussov, L.V., Cohen,S., Jung, H.H., Sup-Soh, K., Lipkind, M., Voiekov, V.L., Slawinski, J., Aoshima, Y., Michiniewicz, Z., van Klitzing,L., Swain,J.:Biophotons (Multi-Author-Review). Indian Journal of Experimental Biology 41 (2003), Vol 5, 391-544.
Popp,F.A., Yan,Yu: Delayed luminescence of biological systems in terms of coherent states. Physics Letters A 293 (2002), 93-97.
Yan, Y., Popp,F.A., Sigrist,S., Schlesinger,D., Dolf,A., Yan,Z., Cohen,S., and Chotia, A.:Further analysis of delayed luminescence of plants, Journal of Photochemistry and Photobiology 78 (2005),229-234.
Popp, F.A., Li, K.H. and Gu,Q. (eds.): Recent Advances in Biophoton Research and Its Applications. World Scientific, Singapore 1992.
Beloussov, L.V. and Popp,F.A. (eds.):Biophotonics. Moscow State University 1994, Bioinform-Services, Russia 1995.
Cohen, S., and Popp,F.A.:Low-level luminescence of the human skin. Skin Research and Technology 3 (1997), 177-180.
Beloussov, L.V., Popp,F.A., Voiekov, V., and van Wijk, R.: Biophotonics and Coherent Systems. Moscow University Press, Moscow 2000.
Popp,F.A. and Beloussov, L.(eds.): Biophotonics. Kluwer Academic Publishers, Dordrecht-Boston-London 2003.
Prasad, P.N.: Introduction to Biophotonics. Wiley, Hoboken, New Jersey 2003.
Van Wijk, R. and Shen, X. (eds.):Biophotonics, Springer, Berlin-Heidelberg-New York 2005.
Biophotons, the light in our cells
Marco Bishop , Zweitausendeins Frankfurt 1998 27100 ISBN
Biological Resonance, Resonance in Biology, Gabor Lednyiczky, Olga Zhalko-Tyarenko Hippocampus Institute Budapest Hungary
Pulsed electromagnetic fields affect osteoblast proliferation and differentiation in bone tissue engineering
Ming-Tzu Tsai 1, Walter Hong-Shong Chang 1 *, Kyle Chang 2, Ru-Jyuan Hou 1, Tai-Wei Wu 1
1Department of Biomedical Engineering, Chung Yuan Christian University, Chung-Li, Taiwan
2Department of Medical Research, Mackay Memorial Hospital, Taipei, Taiwan
The effect of pulsed electromagnetic fields on secondary skin wound healing. An experimental study
Athanasios Athanasiou 1 *, Spiridon Karkambounas 1, Anna Batistatou 2, Efstathios Lykoudis 3, Afroditi Katsaraki 4, Theodora Kartsiouni 1, Apostolos Papalois 5, Angelos Evangelou 1
1Laboratory of Experimental Physiology, Ioannina University School of Medicine, Greece
2Laboratory of Pathology and Anatomy, Ioannina University School of Medicine, Greece
3Department of Plastic Surgery and Burns, Ioannina University School of Medicine, Greece
4Ioannina University Statistics Service, Athens, Greece
5Experimental-Research Unit ELPEN Pharma, Athens, Greece